Soleus Capital Management, L.P. — 13F Holdings & Portfolio
CIK 1802630 · latest 13F-HR filed 2026-08-11
Soleus Capital Management, L.P. manages $2.90B in 13F-reported U.S. long-equity assets across 97 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are KRYS (12.03%), CELC (6.14%), TGTX (5.54%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 22 new positions and exited 18; 34 existing positions rose in reported value and 36 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Loading holdings…
AUM
$2.90B
Long-equity book
Holdings
97
Distinct positions
Period
2026-06-30
Filed 2026-08-11
Q/Q Activity
+22 / −18 / ↑34 / ↓36
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26KRYS12.0% · -18%CELC6.1% · +33%TGTX5.5% · -27%PODD5.5% · +86%NVCR5.2% · -6%UTHR4.2% · +20%INSP3.0% · +235%RIGL2.5% · +18335%ANIP2.5% · +6%BBNX2.4% · +1%VCEL2.2% · -43%PRAX2.0% · -46%GERN1.9% · +3%ALKS1.9% · -48%ERAS1.7% · newNPCE1.6% · -1%PGNY1.6% · -22%INDV1.5% · -16%PBLS1.4% · newFOCL1.3% · newGMED1.3% · -36%RCUS1.2% · +159%SNDX1.2% · -6%NRIX1.2% · +56%LEGN1.2% · newJBIO1.2% · +95%UNH1.1% · newAVTX1.1% · +274%URGN1.1% · +14%MBX1.0% · +188%PALI0.9% · newPHVS0.9% · +4%ORGO0.8% · +0%SUPN0.8% · newPRCT0.8% · +527%TNGX0.8% · +58%IKT0.8% · 0%TRVI0.8% · -27%BMRN0.7% · -42%LIVN0.7% · -56%ARGX0.6% · +470%NVCT0.6% · newCAPR0.6% · newEWTX0.6% · -69%PRLD0.6% · newXENE0.6% · -9%CCCC0.5% · -11%KNSA0.5% · -53%KIDS0.5% · +19%AVLN0.5% · newBDSX0.5% · +41%SYRE0.5% · newTWST0.4% · -92%VIR0.4% · -50%ALNY0.3% · -75%IMVT0.3% · +10%INSM0.3% · +780%SEPN0.3% · 0%SOPH0.3% · -15%NKTR0.3% · new
Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 48.9%Cumulative share of the portfolio held in the largest N positions.
Firm Profile & Key People
As of the firm’s regulatory filing dated Apr 27, 2026.
Assets Under Management
$3.66B
Discretionary
$3.66B
Employees
23
Accounts
14
Address
100 FIELD POINT ROAD
SUITE 200
GREENWICH, CT 06830
SUITE 200
GREENWICH, CT 06830
Phone
(475) 208-3178
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| COPPOLA, MICHAEL, ANTHONY Control | CHIEF FINANCIAL OFFICER since May 2021 | Less than 5% | Individual |
| LEVY, GUY, BEZALEL Control | CHIEF INVESTMENT OFFICER; LIMITED PARTNER since Feb 2018 | 50–75% | Individual |
| MUSUMECI, STEVEN, JOSEPH Control | CHIEF OPERATING OFFICER; LIMITED PARTNER since Feb 2018 | Less than 5% | Individual |
| SCHAAFF, HAROLD, JAMES Control | GENERAL COUNSEL; CHIEF COMPLIANCE OFFICER since Jun 2024 | Less than 5% | Individual |
| SOLEUS GP LLC Control | GENERAL PARTNER since Dec 2017 | Less than 5% | Domestic Entity |
| CANNER, DAVID, ALLEN | LIMITED PARTNER since Apr 2022 | 5–10% | Individual |
| LUND, BENJAMIN, ANDREW | LIMITED PARTNER since Jan 2024 | 5–10% | Individual |
| SP SOLEUS HOLDINGS LLC | LIMITED PARTNER since Jul 2018 | 10–25% | Domestic Entity |
| DAVIS, CHARLES, ARTHUR Control Indirect owner via SP SOLEUS HOLDINGS LLC | MEMBER since Sep 2018 | 50–75% | Individual |
| FRIEDMAN, STEPHEN, NMN Control Indirect owner via SP SOLEUS HOLDINGS LLC | MEMBER since Sep 2018 | 25–50% | Individual |
| LEVY, GUY, BEZALEL Control Indirect owner via SOLEUS GP LLC | SOLE OWNER since Dec 2017 | 75% or more | Individual |
Ownership & leadership changes · 8 filings with changes since Mar 28, 2018
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
Jul 3, 2024 filing
- No longer listedGUY LEVY 2018 GST TR · LIMITED PARTNER · 5–10% · listed since Sep 2018
- No longer listedLEVY, NAVEH · TRUSTEE OF GUY LEVY 2018 GST TR · 5–10% · listed since Sep 2018
- AddedLUND, BENJAMIN, ANDREW · LIMITED PARTNER · 5–10%
- AddedSCHAAFF, HAROLD, JAMES · GENERAL COUNSEL; CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedMUSUMECI, STEVEN, JOSEPH · title CHIEF OPERATING OFFICER; CHIEF COMPLIANCE OFFICER; LIMITED PARTNER → CHIEF OPERATING OFFICER; LIMITED PARTNER
Mar 26, 2024 filing
- No longer listedWILLIAMS, ZACHARY, TYLER · LIMITED PARTNER · 5–10% · listed since Apr 2022
- AddedGUY LEVY 2018 GST TR · LIMITED PARTNER · 5–10%
- AddedLEVY, NAVEH · TRUSTEE OF GUY LEVY 2018 GST TR · 5–10%
- ChangedMUSUMECI, STEVEN, JOSEPH · ownership 5–10% → Less than 5%
Mar 15, 2023 filing
- No longer listedKETNER, BARBARA, LENNOX · LIMITED PARTNER · 5–10% · listed since Jan 2019
- AddedCANNER, DAVID, ALLEN · LIMITED PARTNER · 5–10%
- AddedWILLIAMS, ZACHARY, TYLER · LIMITED PARTNER · 5–10%
Mar 7, 2022 filing
- AddedCOPPOLA, MICHAEL, ANTHONY · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Mar 25, 2021 filing
- AddedKETNER, BARBARA, LENNOX · LIMITED PARTNER · 5–10%
- ChangedLEVY, GUY, BEZALEL · title CHIEF INVESTMENT OFFICER → CHIEF INVESTMENT OFFICER; LIMITED PARTNER
- ChangedMUSUMECI, STEVEN, JOSEPH · title CHIEF OPERATING OFFICER; CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER; CHIEF COMPLIANCE OFFICER; LIMITED PARTNER
May 19, 2020 filing
- ChangedMUSUMECI, STEVEN, JOSEPH · title CHIEF OPERATIONS OFFICER; CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER; CHIEF COMPLIANCE OFFICER
- ChangedSOLEUS GP LLC · title GENERAL PARTNER; SOLE OWNER → GENERAL PARTNER
Mar 30, 2020 filing
- ChangedLEVY, GUY, BEZALEL · ownership Less than 5% → 50–75%
- ChangedSOLEUS GP LLC · ownership 75% or more → Less than 5%
Nov 6, 2018 filing
- AddedDAVIS, CHARLES, ARTHUR · MEMBER · 50–75% · indirect via SP SOLEUS HOLDINGS LLC · control person
- AddedFRIEDMAN, STEPHEN, NMN · MEMBER · 25–50% · indirect via SP SOLEUS HOLDINGS LLC · control person
- AddedSP SOLEUS HOLDINGS LLC · LIMITED PARTNER · 10–25%
- ChangedMUSUMECI, STEVEN, JOSEPH · title CHIEF COMPLIANCE OFFICER → CHIEF OPERATIONS OFFICER; CHIEF COMPLIANCE OFFICER; ownership Less than 5% → 5–10%
Mar 28, 2018 filing (earliest on record)
- ListedLEVY, GUY, BEZALEL · CHIEF INVESTMENT OFFICER · Less than 5% · control person
- ListedLEVY, GUY, BEZALEL · SOLE OWNER · 75% or more · indirect via SOLEUS GP LLC · control person
- ListedMUSUMECI, STEVEN, JOSEPH · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedSOLEUS GP LLC · GENERAL PARTNER; SOLE OWNER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- RIGEL PHARMACEUTICALS INC$71.8M +26570.8%
- INSPIRE MED SYS INC$56.4M +189.9%
- KRYSTAL BIOTECH INC$51.2M +17.2%
- INSULET CORP$41.7M +35.3%
- NOVOCURE LTD$35.8M +31.3%
Top Trims
- TWIST BIOSCIENCE CORP-$47.5M -81.5%
- PRAXIS PRECISION MEDICINES I-$47.1M -44.2%
- ALNYLAM PHARMACEUTICALS INC-$33.6M -77.2%
- MIRUM PHARMACEUTICALS INC-$28.2M -76.3%
- EDGEWISE THERAPEUTICS INC-$27.4M -59.9%
New Positions
- ERASCA INC$49.5M
- PARABILIS MEDICINES INC$40.1M
- LEGEND BIOTECH CORP$34.8M
- UNITEDHEALTH GROUP INC$33.3M
- PALISADE BIO INC$27.3M
Exited Positions
- VAXCYTE INC$22.4M
- ICON PLC$21.2M
- TRAVERE THERAPEUTICS INC$16.2M
- INHIBRX BIOSCIENCES INC$8.8M
- DEXCOM INC$8.8M
Soleus Capital Management, L.P. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $349.1M | 12.03% | 939,254 | SH |
| 2 | CELCUITY INC | CELC | 15102K100 | $178.3M | 6.14% | 1,704,318 | SH |
| 3 | TG THERAPEUTICS INC | TGTX | 88322Q108 | $160.9M | 5.54% | 2,927,895 | SH |
| 4 | INSULET CORP | PODD | 45784P101 | $159.7M | 5.50% | 1,049,000 | SH |
| 5 | NOVOCURE LTD | NVCR | G6674U108 | $150.2M | 5.18% | 9,913,401 | SH |
| 6 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $122.2M | 4.21% | 225,587 | SH |
| 7 | INSPIRE MED SYS INC | INSP | 457730109 | $86.2M | 2.97% | 1,931,436 | SH |
| 8 | RIGEL PHARMACEUTICALS INC | RIGL | 766559702 | $72.1M | 2.49% | 1,843,504 | SH |
| 9 | ANI PHARMACEUTICALS INC | ANIP | 00182C103 | $71.8M | 2.48% | 867,760 | SH |
| 10 | BETA BIONICS INC | BBNX | 08659B102 | $68.8M | 2.37% | 4,393,714 | SH |
| 11 | VERICEL CORP | VCEL | 92346J108 | $64.9M | 2.24% | 1,459,152 | SH |
| 12 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $59.4M | 2.05% | 177,517 | SH |
| 13 | GERON CORP | GERN | 374163103 | $54.8M | 1.89% | 42,808,659 | SH |
| 14 | ALKERMES PLC | ALKS | G01767105 | $53.9M | 1.86% | 1,029,252 | SH |
| 15 | ERASCA INC | ERAS | 29479A108 | $49.5M | 1.70% | 2,700,000 | SH |
| 16 | NEUROPACE INC | NPCE | 641288105 | $46.3M | 1.59% | 2,911,122 | SH |
| 17 | PROGYNY INC | PGNY | 74340E103 | $46.2M | 1.59% | 1,602,000 | SH |
| 18 | INDIVIOR PHARMACEUTICALS INC | INDV | 45579U109 | $43.7M | 1.50% | 1,064,000 | SH |
| 19 | PARABILIS MEDICINES INC | PBLS | 698955101 | $40.1M | 1.38% | 1,465,070 | SH |
| 20 | EDAP TMS S A | FOCL | 268311107 | $37.9M | 1.30% | 7,309,254 | SH |
| 21 | GLOBUS MED INC | GMED | 379577208 | $37.0M | 1.28% | 468,922 | SH |
| 22 | ARCUS BIOSCIENCES INC | RCUS | 03969F109 | $36.0M | 1.24% | 1,168,738 | SH |
| 23 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $35.6M | 1.23% | 1,628,039 | SH |
| 24 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $35.5M | 1.22% | 1,465,163 | SH |
| 25 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $34.8M | 1.20% | 1,205,000 | SH |
| 26 | JADE BIOSCIENCES INC | JBIO | 008064206 | $34.5M | 1.19% | 1,550,690 | SH |
| 27 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $33.3M | 1.15% | 80,000 | SH |
| 28 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $30.6M | 1.05% | 1,654,978 | SH |
| 29 | UROGEN PHARMA LTD | URGN | M96088105 | $30.5M | 1.05% | 829,810 | SH |
| 30 | MBX BIOSCIENCES INC | MBX | 55287L101 | $28.4M | 0.98% | 515,279 | SH |
| 31 | PALISADE BIO INC | PALI | 696389402 | $27.3M | 0.94% | 13,063,687 | SH |
| 32 | PHARVARIS N V | PHVS | N69605108 | $25.3M | 0.87% | 730,907 | SH |
| 33 | ORGANOGENESIS HLDGS INC | ORGO | 68621F102 | $24.6M | 0.85% | 10,140,951 | SH |
| 34 | SUPERNUS PHARMACEUTICALS | SUPN | 868459108 | $24.2M | 0.83% | 520,000 | SH |
| 35 | PROCEPT BIOROBOTICS CORP | PRCT | 74276L105 | $22.6M | 0.78% | 1,003,000 | SH |
| 36 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $22.2M | 0.76% | 709,000 | SH |
| 37 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $22.1M | 0.76% | 10,875,000 | SH |
| 38 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $22.0M | 0.76% | 1,179,618 | SH |
| 39 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $21.5M | 0.74% | 375,572 | SH |
| 40 | LIVANOVA PLC | LIVN | G5509L101 | $21.0M | 0.72% | 254,957 | SH |
| 41 | ARGENX SE | ARGX | 04016X101 | $18.5M | 0.64% | 19,955 | SH |
| 42 | NUVECTIS PHARMA INC | NVCT | 67080T108 | $18.4M | 0.63% | 1,000,000 | SH |
| 43 | CAPRICOR THERAPEUTICS INC | CAPR | 14070B309 | $18.3M | 0.63% | 761,737 | SH |
| 44 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $18.3M | 0.63% | 450,889 | SH |
| 45 | PRELUDE THERAPEUTICS INC | PRLD | 74065P101 | $18.0M | 0.62% | 3,378,378 | SH |
| 46 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $16.1M | 0.56% | 267,000 | SH |
| 47 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $15.8M | 0.54% | 3,377,981 | SH |
| 48 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $15.8M | 0.54% | 246,353 | SH |
| 49 | ORTHOPEDIATRICS CORP | KIDS | 68752L100 | $14.0M | 0.48% | 732,144 | SH |
| 50 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $13.8M | 0.48% | 419,000 | SH |
Filing History
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-11 | $2.90B | 97 | 0001802630-26-000005 |
| 2026-03-31 | 2026-05-14 | $2.47B | 93 | 0001802630-26-000003 |
| 2025-12-31 | 2026-02-12 | $2.71B | 95 | 0001802630-26-000002 |
| 2025-09-30 | 2025-11-14 | $1.99B | 88 | 0001802630-25-000018 |
Filer Information
Address
100 FIELD POINT ROADSUITE 200
GREENWICH, CT 06830
Phone
(203) 542-5527
Filing Manager
Soleus Capital Management, L.P.
GREENWICH, CT
Signatory
Harold Schaaff
Chief Compliance Officer, Soleus Capital Management, L.P.